[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pulse Biosciences CS (PLSE)

Pulse Biosciences CS (PLSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

This Little-Known Biotech Stock Just Hit a New 5-Year High

Author’s note: Since this is a biotech startup without established financials, I think it’s important to share an enhanced description of what the company hopes to accomplish. 

Valued at $2.27 billion, Pulse Biosciences (PLSE) is committed to health innovation using its patented Nano-pulse Stimulation (NPS) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue. 

Fundamentals

See More
  • Market Capitalization, $K 2,145,510
  • Shares Outstanding, K 69,210
  • Annual Sales, $ 350 K
  • Annual Income, $ -72,780 K
  • EBIT $ -78 M
  • EBITDA $ -77 M
  • 60-Month Beta 1.65
  • Price/Sales 6,478.06
  • Price/Cash Flow N/A
  • Price/Book 33.77

Options Overview Details

View History
  • Implied Volatility 80.20% (-2.58%)
  • Historical Volatility 65.04%
  • IV Percentile 3%
  • IV Rank 6.25%
  • IV High 352.51% on 11/20/25
  • IV Low 62.05% on 06/23/26
  • Expected Move (DTE 28) 0.00 (0.00%)
  • Put/Call Vol Ratio 2.00
  • Today's Volume 12
  • Volume Avg (30-Day) 75
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 1,253
  • Open Int (30-Day) 1,655
  • Expected Range 31.11 to 31.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 1
  • High Estimate $-0.31
  • Low Estimate $-0.31
  • Prior Year $-0.28
  • Growth Rate Est. (year over year) -10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.94 +24.54%
on 07/15/26
33.87 -8.30%
on 07/22/26
+5.46 (+21.33%)
since 06/24/26
3-Month
18.36 +69.17%
on 05/06/26
33.87 -8.30%
on 07/22/26
+8.04 (+34.93%)
since 04/24/26
52-Week
12.56 +147.29%
on 11/20/25
33.87 -8.30%
on 07/22/26
+16.19 (+108.88%)
since 07/24/25

Most Recent Stories

More News
This Little-Known Biotech Stock Just Hit a New 5-Year High

Pulse Biosciences (PLSE) just hit a new 5-year high and has strong technical momentum. Shares are up more than 100% over the past 52 weeks. Revenue is projected to surge 652.38% this year and 236.71% next....

PLSE : 30.94 (-0.19%)
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationâ„¢ (nano-PFA or nsPFAâ„¢) technology, today announced it will report business updates...

PLSE : 30.94 (-0.19%)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationâ„¢ (nano-PFA or nsPFAâ„¢) technology, today announced that the Compensation Committee...

PLSE : 30.94 (-0.19%)
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationâ„¢ (nano-PFA or nsPFAâ„¢) technology, today announced that it intends to deliver...

PLSE : 30.94 (-0.19%)
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulseâ„¢ technology using proprietary nanosecond pulsed field ablation (nsPFAâ„¢) energy, today announced plans to participate in the upcoming Goldman...

PLSE : 30.94 (-0.19%)
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulseâ„¢ technology using proprietary nanosecond pulsed field ablation (nsPFAâ„¢) energy, today announced its Co-Chairmen of the Board, Robert Duggan...

PLSE : 30.94 (-0.19%)
Pulse Biosciences Q1 Earnings Call Highlights

Pulse Biosciences (NASDAQ:PLSE) said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new...

PLSE : 30.94 (-0.19%)
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulseâ„¢ technology using proprietary nanosecond pulsed field ablation (nsPFAâ„¢) energy, today announced plans to participate in the upcoming BofA...

PLSE : 30.94 (-0.19%)
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Accelerates Enrollment Timeline for the Cardiac Catheter IDE Conference Call to Be Held Thursday, May 7th to Discuss Business Updates and Financial Results...

PLSE : 30.94 (-0.19%)
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulseâ„¢ Cardiac Catheter System at Heart Rhythm 2026

Multicenter results show sustained high durability and procedural efficiency, redefining positive expectations for catheter ablation in patients with atrial fibrillation

PLSE : 30.94 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pulse Biosciences, Inc. is a medical device company. It is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling. NPES provide effective local tumor control and to initiate an adaptive immune response. The company deploy NPES platform applications...

See More

Key Turning Points

3rd Resistance Point 34.58
2nd Resistance Point 33.67
1st Resistance Point 32.33
Last Price 30.94
1st Support Level 30.08
2nd Support Level 29.17
3rd Support Level 27.83

See More

52-Week High 33.87
Last Price 30.94
Fibonacci 61.8% 25.73
Fibonacci 50% 23.21
Fibonacci 38.2% 20.70
52-Week Low 12.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.